{"url":"https://lda.senate.gov/api/v1/filings/cef3b7b2-e609-4d36-af5c-d009511d02df/","filing_uuid":"cef3b7b2-e609-4d36-af5c-d009511d02df","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/cef3b7b2-e609-4d36-af5c-d009511d02df/print/","filing_document_content_type":"text/html","income":null,"expenses":"870000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-20T17:35:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 New Jersey Ave NW","registrant_address_2":"Suite 850","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":16032,"url":"https://lda.senate.gov/api/v1/registrants/16032/","house_registrant_id":31463,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","description":"Association representing the interests of the generic pharmaceutical industry.","address_1":"601 New Jersey Ave NW","address_2":"Suite 850","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK RATNER","contact_telephone":"+1 202-249-7100","dt_updated":"2026-07-29T08:15:25.555128-04:00"},"client":{"id":121533,"url":"https://lda.senate.gov/api/v1/clients/121533/","client_id":12,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-01-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription Drug Costs. Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes (H.R.1051). S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Quotas on Controlled Substances. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. H.R.7148: Consolidated Appropriations Act, 2026 as it relates to PBM reforms and Q1/Q2. H.R.8339: Drug Origin Transparency Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153755,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"KEETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation. CMS RFC on Domestic Manufacturing. CMS Final Rule on Bona Fide Service Fees. HCPCS Codes. Tiering. PBM Bid Transparency.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153755,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"KEETON","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"General Trade Issues. Drug Supply Chain. Rules of Origin. Country of Origin Labeling. Tariffs on Generic Medicines. Quotas on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. United States-Mexico-Canada Agreement. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":184,"name":"U.S. Customs & Border Protection"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FDA Funding.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}